Correlation of Portal and Peripheral Venous ctDNA in Pancreatic Adenocarcinoma

Other illness

• Other active cancer or haematological malignancy
• Uncontrolled major infections, chronic infectious diseases, immunodeficiency syndromes
• Premalignant hematological disorders, e.g. myelodysplastic syndrome
• Severe hepatic impairment
• Pregnant, parturient or breast-feeding woman (a pregnancy test will be carried out unless there is a history of hysterectomy, tubal ligation or menopause)
• History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol, or to prevent him/her from giving informed consent.

Lab values

• Uncontrolled congestive heart failure - untreated angina pectoris; recent myocardial infarction (within the last year) - uncontrolled hypertension (SBP \> 160 mm or DBP \> 100 mm, despite optimal drug therapy), long QT.

Other

• Patients not registered with social security
• Person deprived of liberty by an administrative or judicial decision, or person placed under court protection, sub-guardianship or guardianship.
• Treatment contraindicated for venous sampling

• Age ≥ 18 years
• Patient with operable pancreatic adenocarcinoma (resectable or boderline with or without neoadjuvant therapy) with histological evidence or indirect diagnostic criteria (CA 19-9 Significant (≥ 200 U/ml), pancreatic hypodense lesion without differential diagnosis)
• Biological criteria: Neutrophils \> 1,500 cmm, platelet count \> 100,000 cmm, creatinine clearance (Cockroft and Gault equation) \> 60 ml/min, hemoglobin \> 10 g/dl.
• ECOG performance status 0 or 1
• Patient has read and understood the information letter and signed the non-opposition/consent form.
• For an adult unable to give consent: Representative of the adult who has read and understood the information letter and signed the consent form